406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment
In a Nutshell
Headache disorders lack biomarkers and rely on clinical criteria: tension-type headache is bilateral, non-throbbing, and mild; migraine requires 4-72 hour attacks with nausea or both photophobia/phonophobia plus two of unilateral, throbbing, movement-aggravated, moderate-severe pain; cluster headache is unilateral, periorbital, 15 min-3 hr, with autonomic features and marked restlessness. Only ~50 new headache specialists finish training yearly despite migraine affecting 12% of people; preventive therapy (CGRP mAbs, topiramate, propranolol, Botox for chronic migraine) is indicated once attacks become frequent or disabling, yet only 16-17% of eligible patients receive it. Acute treatment favors migraine-specific triptans or gepants over opioids/barbiturates, which risk medication-overuse headache; lifestyle regularity, headache diaries, and addressing comorbidities (sleep apnea, obesity, mood disorders) are essential to prevent chronification.
These notes were generated by AI and may contain inaccuracies.
Brian Grosberg is a neurologist specializing in headache medicine. Headache is one of the most common neurologic symptoms, with nearly every person experiencing a headache at some point. Medical education provides minimal headache training, with medical students and neurology residents receiving only a few hours of lectures across their entire training.
Grosberg entered the field by accident during his first month of neurology residency when caring for a litigator disabled for six weeks by a prolonged migraine. His future mentor recognized his detailed history-taking ability and offered additional training. Grosberg pursued headache medicine training on his own time during residency, working with his mentor after long hospital shifts, then completed formal fellowship training.
No biomarkers exist for headache diagnosis. Neither CT scans nor MRIs reveal the source of pain. The International Classification of Headache Disorders serves as the diagnostic reference and categorizes headaches as primary or secondary.
Primary headaches are syndromes in themselves, not attributable to another condition. The most common include migraine, tension-type headache, and cluster headache.
Secondary headaches are attributable to an underlying condition. Examples include medication overuse headache from frequent acute pain medication use, and caffeine withdrawal headache. These are not life-threatening but have pathophysiological mechanisms.
Tension-type headache is the most common headache people experience. Characteristics include:
- Bilateral pain affecting both sides of the head, face, or neck
- Mild to moderate intensity
- Non-pulsating, non-throbbing quality
- May include light or sound sensitivity but never both
- No nausea
- Duration from 30 minutes to one week
This type of headache is often manageable without significant functional impairment.
Migraine diagnosis requires at least five lifetime attacks lasting 4-72 hours untreated or unsuccessfully treated, with at least two of the following four qualities:
- Unilateral pain (though up to 40% of migraine patients experience bilateral pain)
- Pulsating or throbbing quality
- Avoidance of light and routine physical activity
- Presence of light sensitivity, sound sensitivity, or nausea/vomiting
People need not have nausea if they have both light and sound sensitivity. If lacking nausea, light sensitivity, and sound sensitivity, migraine is unlikely.
Allodynia is an uncomfortable sensation to normally non-painful stimuli, present in approximately two-thirds to 70% of migraine patients. Examples include discomfort from pulling hair back in a ponytail, brushing hair, wearing tight hats, or wearing glasses resting on the nose. This phenomenon makes certain migraine-specific treatments like triptans less effective if delayed.
Migraine consists of distinct but sometimes overlapping phases. The premonitory phase occurs hours to days before headache onset and includes yawning, food cravings, tiredness, irritability, light sensitivity, and neck stiffness. This phase was studied for early intervention treatment.
Approximately one-quarter to one-third of migraine patients experience aura, a reversible neurologic phenomenon caused by cortical spreading depolarization. A wave of excitability starts in the visual cortex at the back of the brain, followed by a period of relaxation.
Visual aura is most common, featuring positive and negative phenomena including zigzag lines, difficulty seeing on one half of the visual field, spots, black spots, and distortions. Aura evolves gradually over 5-60 minutes.
Aura must be distinguished from TIA or stroke. Distinguishing features include:
- History of migraine
- Gradual evolution over 5-60 minutes versus maximal onset in stroke
- Sequential progression of symptoms
- Positive and negative visual phenomena versus negative phenomena only in stroke
- Aura symptoms typically affecting one half of the visual field
Migraine affects 12% of the population, approximately one billion people worldwide and 45 million in the United States. Women are affected three times more often than men, with approximately 18% of women experiencing migraine.
Economic impact reaches billions of dollars in the workplace through both absenteeism and presenteeism. Presenteeism, where individuals are present but not functioning at full capacity, represents the heaviest burden and is difficult to quantify.
The migraine spectrum is broad. While some patients are bedridden during attacks, many continue functioning while significantly impacted, dimming lights or pushing through symptoms. Migraine is an invisible disease often dismissed as "just a headache" rather than recognized as a neurologic condition.
Episodic migraine involves fewer than 15 headache days per month.
Chronic migraine involves 15 or more headache days per month, affecting 1-2% of the population. These patients experience headaches more than 50% of the time and represent the majority of Grosberg's patient population.
Only approximately 50 fellowship-trained headache neurologists complete training annually. This shortage is significant given that migraine affects 12% of the population. Demand for headache specialists far outstrips supply.
The transcript ends with discussion of genetic factors in migraine.
Women are three times more likely than men to experience migraine, raising questions about the role of hormones. Estrogen and progesterone receptors exist in the brain, suggesting hormonal influence. The frequency of migraine appears higher during reproductive years and fluctuates across hormonal milestones including puberty, menses, pregnancy, lactation, perimenopause, and menopause. Genetics plays a significant role, with family history increasing likelihood of experiencing migraine. Migraine is multifactorial, involving both genetic and environmental factors.
Approximately two-thirds of women experience migraines with perimenstrual attacks or note an association around their menstrual period. Pure menstrual migraine, where attacks occur solely around menses, affects less than 10% of women. Menstrual-related migraine, present in about 50% of women, involves attacks both during menses and at other times of the month.
Studies dating back to the 1970s identified the natural decline in estrogen during the late luteal phase as a trigger for migraine. The key factor is the faster rate of estrogen decline, not the decline itself. This rapid decline is unique to women who experience migraine. Post-ovulation sharp decline in estradiol does not appear to carry the same risk. The combination of estrogen and progesterone decline at the end of the luteal phase may contribute, though current belief centers on estrogen decline.
Estrogen affects serotonin transmission, which is involved in migraine pathophysiology. Serotonin levels were found to be lower in blood during migraine attacks and recover during the recovery phase, leading to the development of triptans.
Studies have examined giving physiologic estrogen replacement to susceptible women during anticipated estrogen crashes. Results are mixed: some women experience improvement in migraine, others show no improvement, and some taking combined hormonal contraceptives experience worsening. Predicting individual response is difficult. Collaborative care with gynecologists specializing in hormones helps map individualized treatment plans.
Migraine is highly genetic but polygenic rather than caused by a single gene. The nervous system of people with migraine is more hyperexcitable than those without. This manifests as increased sensitivity to light and sound rather than objectively louder or brighter stimuli.
An evolutionary benefit hypothesis suggests that hyperexcitability may have provided advantages to women as family caregivers, allowing them to detect inclement weather or signs of danger. Women generally have neural networks better suited for multitasking, which may represent an evolutionary trade-off where migraine represents an extreme manifestation.
Triggers are factors that elicit headaches in biologically predisposed individuals, not the cause of headaches. Common triggers include changes in weather, the let-down phenomenon after stress, and certain foods or drinks. Usually, a combination of two or more triggers precipitates migraine attacks. The subset of patients triggered by weather patterns and barometric pressure varies individually.
Patients experiencing 15 or more headache days per month may report more triggers due to reporting bias. A detailed 15-page questionnaire helps determine whether headaches are primary or secondary and how migraine presents in individual patients.
A headache diary is the most important tool for patients and clinicians. It captures rich, temporally-related information that exceeds data from electronic trackers. Several months of diary data is needed, particularly when assessing menstrual-migraine relationships, requiring at least two out of three cycles to confirm perimenstrual migraine diagnoses.
During perimenopause to menopause transition, hormonal fluctuations occur alongside migraine changes. About two-thirds of women notice improvement after completing perimenopause, while 10-20% may continue or worsen. A common fallacy suggests migraine resolves at menopause. Risk factors for more frequent migraine include five or more headache days per month, sleep disturbance, and mood changes. HRT dosing must be individualized, as some women need no hormone therapy while others require it despite non-medication approaches.
Not all migraine sufferers experience all phases. The premonitory phase occurs first, followed by aura in one-quarter to one-third of patients, then the migraine phase with pain plus light sensitivity, sound sensitivity, nausea, and autonomic symptoms. Autonomic symptoms include tearing, eye redness, nasal congestion, or runny nose, often leading to misdiagnosis as "sinus headache." No such thing as sinus headache exists; acute or chronic rhinosinusitis are the proper terms.
The postdrome phase follows pain resolution, leaving patients feeling hungover for hours to days. Population and clinic-based studies show 60-80% of patients experience this postictal period. Interictal burden refers to anticipatory planning around potential migraine attacks, affecting daily activities and vacation planning.
Tension-type headache is the most common headache disorder with high lifetime prevalence and relatively even sex distribution. Despite the name, tension or stress is not necessarily the cause. Patients experience no light or sound sensitivity, mild to moderate pain around the head, neck muscle involvement, and percranial muscle-nerve tenderness. Genetic and environmental factors contribute.
Response to 1,000 milligrams of acetaminophen does not confirm tension-type headache diagnosis. Proper diagnosis requires meeting criteria and ruling out secondary causes.
Cluster headache is relatively uncommon but one of the most painful disorders known. A patient described it as "giving birth to 100 babies at the same time without an epidural." It disproportionately affects men (3-4:1 ratio) with circadian periodicity, peaking during longest and shortest days (January-February, July-August).
Pain is sidelocked, around or behind one eye, with rapid onset (5-15 minutes peak versus gradual migraine buildup). Attacks last 15 minutes to 3 hours with stabbing, boring quality. Associated features include eyelid droop, tearing, eye redness, nasal congestion, or runny nose in 97% of patients. Restlessness occurs in 90% of patients, contrasting with migraine preference for stillness.
Called "suicide headache" due to pain intensity and attack frequency (average 3 attacks daily, ranging from every other day to 8 daily). Cluster periods last weeks to months in episodic form, or continuously in chronic form.
First-degree relatives have higher risk. Despite being highly motivated patients, cluster headache is often underdiagnosed or misdiagnosed. January-February attacks may be misdiagnosed as sinus infections, July-August attacks as allergies, and facial pain may lead to unnecessary dental or sinus surgery.
Patients can use downloadable headache logs to take an accurate history and present it to their primary care physician. The goal is to highlight red flags that indicate cluster headache, which may warrant referral to a headache specialist despite the limited availability of such specialists. Primary care physicians face time constraints, typically having only about 10 minutes per patient, making it difficult for them to elicit detailed headache histories. When patients bring comprehensive data from headache logs, it allows primary care physicians to make informed decisions about diagnosis and referral without needing to conduct the full detailed assessment themselves.
The challenge extends beyond initial diagnosis to navigating the healthcare system after the gateway visit to primary care. Many patients with cluster headache present to specialists after being misdiagnosed or remaining undiagnosed. Cluster headache has earned the nickname "suicide headache," which influences triage decisions in specialist offices. Patients who report cluster headache symptoms through questionnaires are often prioritized for quicker appointments due to the severity of the condition.
Cluster headache treatment requires a multi-pronged approach involving acute, preventive, and transitional therapies. Acute treatment focuses on rapidly aborting pain during an attack. Preventive treatment involves taking one or more medications to prevent attacks, particularly important for patients experiencing multiple attacks per day over weeks to months. Transitional treatment bridges the gap while preventive medications build up to therapeutic levels, which can take weeks to months even for migraine.
Lifestyle modifications for cluster headache include avoiding alcohol, avoiding foods with nitrates, avoiding daytime naps, and addressing sleep apnea since hypoxia can trigger attacks. These interventions work alongside pharmacological preventive treatments that require time to reach full effectiveness.
Migraine has specific identified risk factors that differ from cluster headache. Studies show that experiencing at least one migraine per week increases risk for more frequent attacks. Higher baseline frequency of attacks may lead to chronification or transformation to more frequent migraine. Stressful life events represent a risk factor, as does sleep disturbance including insomnia and sleep apnea.
Mood disorders such as depression and anxiety have a bidirectional relationship with migraine, coexisting at higher rates than expected by chance. Addressing these comorbidities is essential because migraine treatment requires addressing all risk factors, not just pain management. Frequent use of acute pain medications (two or more days per week regularly) can paradoxically create more frequent headaches through medication overuse. This applies to NSAIDs, acetaminophen, triptans, barbiturate-containing combination analgesics like Fioricet, and opioids.
Obesity is a significant risk factor for more frequent migraine, with the relationship being dose-dependent. Morbidly obese individuals (BMI 35+) face five times higher risk for more frequent migraine, while those with BMI 30-35 have approximately double the risk. Weight loss through both surgical and non-surgical methods has shown improvement in migraine symptoms, though not uniformly across all individuals.
Other pain disorders including joint pain, neck pain, and back pain independently increase migraine risk. Untreated or suboptimally treated nausea during migraine attacks also contributes to greater risk. The presence of other pain disorders may lead to increased medication use, which then becomes an additional trigger.
Cluster headache triggers differ from migraine risk factors. Cluster headache involves particular triggers like nitrates, sleep apnea, and daytime napping, while migraine requires addressing broader risk factors to prevent disease progression. Cluster headache pathophysiology involves the sleep-wake cycle with hypothalamic and pineal gland involvement, creating circannual and circadian periodicity. Patients often report cluster attacks coinciding with daylight saving time changes in both spring and fall.
The approach to lifestyle modification is highly individualized, considering the specific diagnosis, coexisting medical conditions, patient preferences, and expectations. Before visits, patients are asked what one or two most important questions need answering to align medical recommendations with their perspective. Diet recommendations include routine meals that are not delayed, with particular food triggers tracked via headache diaries rather than blanket elimination diets unless family history suggests gluten sensitivity or celiac disease.
Sleep regularity is emphasized because migraine involves hypersensitivity, and irregular patterns can trigger attacks. Stress reduction through meditation, biofeedback, and cognitive behavioral techniques forms part of the holistic approach. Weekend migraine attacks often result from the combination of delayed sleep, delayed caffeine intake, and endorphin level changes from the work week to weekend transition.
Headache diaries covering a month-long view provide essential data for clinical decision-making. The diaries empower patients while guiding treatment choices. For menstrual migraine, diary data showing consistent timing relative to menstrual cycles enables preemptive treatment strategies that start before anticipated attacks and continue through the expected period.
The diary captures timing of sleep, wake times, menstrual cycle characteristics, caffeine intake, alcohol consumption, and work patterns. This detailed tracking allows clinicians to identify trigger patterns that patients might not recognize, such as delayed caffeine consumption on weekends compared to weekday routines.
Preventive therapy aims to reduce frequency, intensity, or duration of attacks rather than cure migraine. Additional benefits include improving responsiveness to acute treatments, reducing disease burden and progression, improving comorbidities like sleep or weight, enhancing functionality and quality of life, and reducing interictal burden including anticipatory anxiety.
Indications for preventive medication include frequent attacks, disabling attacks despite acute treatment, rare migraine types that limit acute treatment options, or when acute treatments are contraindicated, poorly tolerated, or ineffective. Population-based studies suggest approximately 40% of people with migraine may be medically eligible for preventive therapy, yet only 16-17% actually receive it, creating a significant treatment gap.
For cluster headache, the vast majority of patients require preventive therapy unless the cluster period is unusually brief (one week). Patients experiencing cluster periods lasting weeks to months need preventive treatment. For tension-type headache, the need for prevention depends on frequency: episodic tension-type headache occurs fewer than 15 days per month, while chronic tension-type headache occurs 15 or more days per month. The decision for preventive therapy in tension-type headache depends on frequency, responsiveness to acute treatments, functionality, and quality of life impact.
Beta blockers remain a class of medications used for headache prevention. These blood pressure medications have established use in migraine prevention, though the exact mechanism of action in headache prevention continues to be studied.
The exact mechanism by which beta blockers work for migraine prevention isn't known. It's postulated that they may have effects on the sympathetic aspect of the nervous system. Two beta blockers are FDA approved for this use: propranolol and timolol, though other beta blockers are used as well. They can be very effective for people. Caution is needed if somebody has asthma, as some types of beta blockers can potentially exacerbate it. Potential side effects include lowering of blood pressure, heart rate, or exercise intolerance. It's really important to understand the person so that preventive treatment aligns with that person's lifestyle, risk factors, and comorbidities.
Antidepressants have been used for years for migraine prevention. The term "antidepressant" is considered a poor name for this class of drug. Many supplements or medications used for prevention of migraine weren't specifically designed for migraine prevention, but through serendipity or studies were found to be helpful. Using one of these medications doesn't mean that patients have high blood pressure or depression. While depression or anxiety can exist at a higher than expected rate in migraine patients, patients should not assume that's the indication for use.
The doses often used for migraine prevention are not even starting doses for treating depression. Medications like amitriptyline and nortriptyline are often used at much lower doses than would be needed to treat depression, and rarely are these medications used to treat depression anymore. They can be very effective. One potential side effect is tiredness, so they're usually taken before sleep. For people with migraine who have insomnia, this potential side effect of tiredness may actually be helpful.
These medications are believed to work through effects on serotonin and norepinephrine.
Two anti-seizure medications are FDA approved for migraine prevention: topiramate (Topamax) and valproic acid (Depakote). Topiramate works on particular channels and also has effects on glutamate (the excitatory neurotransmitter in the brain) and GABA (the suppressor neurotransmitter). Valproic acid also has effects on GABA and may be helpful, but has potential side effects.
When prescribing to women during their reproductive years, it's important to understand if they're sexually active and what form of contraceptive they're on. This information is critical because some medications may not be safe during pregnancy, so counseling on this possibility is essential when setting a preventive plan.
The class of drugs called CGRP (calcitonin gene-related peptide) antagonists represents a major advancement. The brain itself is insensate and not pain sensitive, but the coverings around the brain like the meninges (specifically the dura) and the blood vessels within the dura and in the brain have pain-sensitive nerve terminals. The main nerve involved in migraine is the trigeminal nerve.
Historically, in the 1940s, there was a vascular hypothesis of migraine suggesting it was purely a vascular phenomenon with dilation during the pain phase and constriction during recovery. Over the past 50 years, research has established that migraine is a neurovascular phenomenon involving both the nervous system and cranial blood vessels.
Pain-sensitive information is conveyed from pain-sensitive structures (dura mater and dural/intracranial blood vessels) and relayed centrally along the trigeminal nerve. The first division (ophthalmic division) of the trigeminal nerve passes through the trigeminal ganglion and synapses in the trigeminal nucleus caudalis in the brainstem. Nerves supplying sensation to the back of the head, neck, and shoulders from the upper cervical roots (C1, C2, C3, primarily C2 and C3) carry information into the same brainstem area, explaining why migraine patients often have associated neck pain.
When these nerves become stimulated, patients can experience peripheral sensitization (throbbing sensation when turning head or bending down, occurring early in migraine) and, with sustained firing, central sensitization. A clinical marker for central sensitization is allodynia - an uncomfortable sensation to things that normally aren't uncomfortable, such as putting hair in a tight ponytail or brushing hair. This typically kicks in 30 to 60 minutes into a migraine headache, and triptans may be less effective during this time.
Pain-sensitive information travels from the brainstem to the thalamus (sensory processing area), specifically nuclei like the ventroposterolateral nuclei, then to the sensory cortex and other pain matrix areas. During this process, there's a cascade involving a reflex with parasympathetic information in the brainstem, explaining autonomic symptoms (tearing, eye redness, nasal congestion or runny nose). Parasympathetic innervation is relayed to cranial blood vessels, causing dilation and release of chemical messengers including substance P, neurokinin, and CGRP. There's also a pro-inflammatory response called neurogenic inflammation, with release of histamine, mast cells, and nitric oxide.
Studies of jugular venous blood noted elevations of CGRP during migraine. When patients were treated with sumatriptan, their CGRP levels normalized. This led to the development of CGRP antagonists.
CGRP antagonists fall into two categories: large monoclonal antibodies and small molecules called gepants. Three monoclonal antibodies are self-injection medications, administered like EpiPens. These have a long half-life of roughly 28 days and are given monthly. One is given quarterly as an infusion every 3 months.
There are no large head-to-head studies comparing these medications, making it difficult to answer questions about relative efficacy. Treatment decisions may be influenced by what insurance will allow. The home-use pen may be started first because it's easier and potentially cheaper.
These medications represent the biggest change seen in clinical practice for migraine treatment. They work for up to 60% of patients with migraine. Some patients respond within the first month, while others may take up to 3 to 4 months. Success is defined as at least a 50% reduction in headache frequency. The response spectrum includes partial responses, and diaries are important for understanding variable improvement patterns.
If somebody doesn't respond to one treatment within the class, that doesn't mean they won't respond to another. Different drugs have different patents and IP, meaning they can't be the same molecule and could bind to different parts of the epitope. Without biomarkers, it's impossible to predict which medication in the class will work for a given patient.
Gepants are oral small molecule CGRP antagonists with shorter half-lives. A couple are oral, and one is a nasal spray. These can be used acutely during migraine. One medication, atogepant, has an indication for preventive treatment. Rimegepant (Nurtec) has indications for both preventive and acute treatment. Ubrogepant (Ubrelvy) has FDA approval for acute treatment of migraine.
All these medications are expensive. Insurance coverage is variable depending on plans, deductibles, and co-pays. Some patients find it cheaper to fly out of the country to obtain these drugs. The cost of medications may be expensive but is trivial compared to the economic and personal costs of emergency room visits, lost work time, and reduced productivity.
Calcium channel blockers don't have as much data for migraine prevention but are more classically used for cluster headache prevention. They may still be used for migraine prevention at lower doses, though doses are sometimes increased for cluster headache. For normotensive patients with cluster headaches, verapamil may be used in collaboration with a cardiologist. One patient was on over 1,000 milligrams of verapamil - an exceedingly high dose requiring EKG, blood pressure, and pulse monitoring. This patient tolerated it well and had significant reduction in cluster headache frequency.
Surprisingly, Botox doesn't work well for tension-type headache. Its use for migraine was discovered serendipitously when plastic surgeon Bill Binder in California was administering it cosmetically and patients reported their headaches and migraines were improving. This led to studies of onabotulinum toxin (Botox) for prevention of chronic migraine - defined as 15 or more days of headache per month, which is where it has current FDA approval.
Botox doesn't work through cosmetic effects but interferes with release of certain SNARE and SNAP proteins and also affects CGRP. The current protocol is called the PREEMPT protocol, standard worldwide, with injections given in the forehead, sides of the head, back of the head, neck, and shoulders around areas with superficial nerves. The mechanism involves interference with release of vesicles and SNARE/SNAP proteins as well as CGRP.
Insurance companies typically require patients to fail at least two or three conventional non-migraine specific preventive therapies before approving Botox for chronic migraine prevention.
Two main categories exist for acute headache treatment: non-migraine specific and migraine specific medications.
Non-Migraine Specific Options
- Analgesics such as acetaminophen
- NSAIDs
Opioids and Medication Overuse
Opioids and barbiturate-containing combination analgesics like Fioricet or Fiorinal carry the highest risk for medication overuse headache, which is a major risk factor for migraine chronification. These medications may trigger nervous system changes even when used only a handful of times per month. In clinical practice, opioids are considered last-line treatment after all other options have been explored. Emergency departments also avoid opioids due to this potential risk.
Ergotamines
Ergotamines predate triptans and derive from a specific type of fungus. They affect serotonin receptors along with other receptor types.
Triptans
Triptans were the first medications specifically designed for acute migraine treatment. They work selectively on 5HT1B and 5HT1D receptors. The 5HT1B receptors affect smooth muscle cells while the 5HT1D receptors influence neurotransmitter release. Sumatriptan was the first triptan available in tablet and injection form, later joined by six additional triptans for a total of seven medications.
Triptan Selection Factors
Triptans vary in onset speed, duration of action, and formulation options including tablets, melts, nasal sprays, and injections. Selection depends on attack profile, presence of nausea, and gastric motility issues during attacks. Side effects may include warmth, heat, tightness, or flushing that typically resolves quickly but can be uncomfortable for some patients.
Formulation Considerations
Intramuscular injection provides the fastest onset but may intensify side effects. Nasal spray bioavailability varies by formulation - sumatriptan nasal spray has lower bioavailability than alternatives like zolmitriptan (Zomig) nasal spray or zavegepant nasal spray. The injection form of sumatriptan is particularly valuable for cluster headache, with median time to pain relief around 9 minutes.
Acute treatment success is measured by:
- Speed of onset
- Improvement in associated symptoms
- Functionality at 2 hours
- Recurrence rate within 24 hours
Different triptans show varying recurrence rates, influencing treatment selection based on individual patient factors.
Neuromodulation devices use external stimuli (magnetic or electrical) to target the nervous system without implantation.
Available Device Types
- Trigeminal nerve stimulation device applied over the eyebrow
- Vagus nerve stimulation device
- Remote electrical neuromodulation armband (Nerivio) that stimulates arm nerves to activate brain's natural pain downregulation mechanisms
- Combined frontal and occipital nerve stimulation device
Device Applications
These devices can serve as first-line treatment, adjunctive therapy, or rescue treatment depending on patient preferences and attack profiles. Some devices are purchased outright, others leased monthly, and some receive insurance reimbursement. The armband device has FDA clearance for both prevention and acute treatment.
Special Populations
Neuromodulation devices may be considered during pregnancy due to their non-pharmacologic mechanism, though only one device has been specifically studied for acute treatment during pregnancy.
Approximately one-third of patients in academic headache programs report cannabinoid use. However, standardization challenges, lack of controlled trials, potential drug interactions, and difficulty distinguishing direct versus indirect benefits (through improved sleep or anxiety) limit clinical guidance. Regulatory constraints make randomized controlled trials difficult to conduct.
Patient Empowerment
Patients should maintain detailed headache logs and provide comprehensive information to clinicians. Lifestyle factors remain critically important and cannot be overstated.
Treatment Expectations
Preventive medications may take weeks to months to show benefit. Multiple preventive medications may be needed, and treatment requires a tailored approach rather than one-size-fits-all solutions. Acute treatment may require backup or rescue options.
Status Migrainosus
For prolonged attacks lasting longer than three days, intravenous medications may be necessary.
New onset headaches or changes in established headache patterns warrant medical evaluation. Key concerning features include:
- Associated fevers or rashes
- Neck stiffness with difficulty touching chin to chest
- Unintended weight loss
- Immunosuppressive medication use
- Neurologic symptoms (weakness, numbness, speech problems, double vision, balance issues)
- Age over 50 with new headache pattern
- Thunderclap presentation (maximal intensity within seconds to one minute)
- Headaches provoked by cough, exertion, sexual activity, or sleep
- Positional headache components
- Interscapular pain
Pregnancy Considerations
Migraine without aura typically improves during pregnancy, with approximately 47% of women noting improvement in the first trimester and 80-87% in the second and third trimesters.
Temporal Arteritis
This condition should be considered in patients over 50 with new headache patterns. Pain may occur anywhere in the head or face, not just the temples.
CSF leaks may present with positional headaches that worsen when sitting or standing, sometimes developing as a "second-half-of-the-day syndrome." Spontaneous leaks can present as thunderclap headaches. Interscapular pain may also occur. Specialized programs exist for diagnosis and treatment of these cases.
The practice operates one of the largest headache programs in the country with multiple colleagues sharing the same treatment philosophy. Patients from out of state are advised to maintain a local physician for medication management and plan implementation.
Keep Peter Attia MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
